Hello! Welcome to the official website of Betta Pharmaceuticals!
Helpline:0571-86130357     Add to Favorites | Online Feedback 中文
2003
In January 2003, Betta Pharmaceutical was incorporated in Hangzhou;
In August 2003, the Innovative Drug R&D Center was established in Beijing;
2006
In June 2006, Icotinib Hydrochloride Tablets (Conmana) was permitted to be used in Phase I clinical trials upon approval from China Food and Drug Administration;
In December 2006, built its own production base in Hangzhou Yuhang Economic and Technological Development Area;
2007
In March 2007, acquired the patent licensing for invention from the State Intellectual Property Office of the P.R.C. for Icotinib Hydrochloride Tablets (Conmana);
In September 2007, acquired a R&D Tower with independent property in Beijing;
2008
In December 2008, received Phase II b/III clinical approval for Icotinib Hydrochloride Tablets (Conmana) and officially entered Phase II b/III clinical studies;
2010
In April 2010, Eli Lilly and Company invested in Betta;
In April 2010, finished Phase II b/III clinical study of Icotinib Hydrochloride Tablets (Conmana);
2011
In June 2011, received marketing approval for Icotinib Hydrochloride (Conmana);
In August 2011, held the launching press conference at the Great Hall of the People for Icotinib Hydrochloride Tablets (Conmana) in Beijing;
In September 2011, expanded the Beijing R&D Center, which was moved to a 4000 square-meter independent lab building;
In November 2011, officially launched the post-marketing Phase IV clinical study of Icotinib Hydrochloride Tablets (Conmana);
2012
In July 2012, Icotinib Hydrochloride Tablets (Conmana) were included in the 2012 Global Innovative Drugs Research and Development Directory as China’s first innovative drug;
In July 2012, Icotinib Hydrochloride Tablets (Conmana) were incorporated in the Serious Diseases Medicaid of Qingdao;
2013
In January 2013, the grand 10th Anniversary Celebration of the company, “10-Years of Dream Building, A Glorious Journey” was held at the Great Hall of the People of Zhejiang Province;
In February 2013, Icotinib Hydrochloride Tablets (Conmana) were incorporated in the Medical Insurance coverage of Zhejiang Province;
In August 2013, the ICOGEN research results from Phase III clinical trial of Icotinib Hydrochloride Tablets (Conmana) was published on world-renowned academic journal, The Lancet, in full text;
In September 2013, the company and Amgen co-founded Betta Amgen Pharmaceutical Co., Ltd.;
In December 2013, the company’s 147 mu new production base officially broke ground;
2014
In June 2014, China Securities Regulatory Commission officially accepted the company’s IPO application documents;
In October 2014, the company signed a contract with Xcovery to jointly develop a new generation ALK inhibitor;
In November 2014, Icotinib Hydrochloride Tablets (Conmana) was allowed to be used in first-line treatment of patients with advanced-stage NSCLC with EGFR mutation upon approval from China Food and Drug Administration.